Home  |  Contact

Cellosaurus MCF-7/LY2 (CVCL_9579)

[Text version]

Cell line name MCF-7/LY2
Synonyms LY2; LY-2
Accession CVCL_9579
Resource Identification Initiative To cite this cell line use: MCF-7/LY2 (RRID:CVCL_9579)
Comments Part of: GrayJW Breast Cancer Cell Line Panel.
Doubling time: 56.10 hours (https://www.synapse.org/#!Synapse:syn2347014).
Selected for resistance to: ChEBI; CHEBI:90187; Lilly 117018 (LY 117018).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (from parent cell line).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*02:01,02:01
HLA-BB*44:02,18:01
HLA-CC*05:01,05:01
Class II
HLA-DQDQA1*01:02,01:02
DQB1*06:02,06:02
HLA-DRDRB1*15:01,15:01
Disease Invasive ductal carcinoma, not otherwise specified (NCIt: C4194)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0031 (MCF-7)
Sex of cell Female
Age at sampling 69Y
Category Cancer cell line
Web pages https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
Publications

PubMed=4029083; DOI=10.1210/endo-117-4-1409
Bronzert D.A., Greene G.L., Lippman M.E.
Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.
Endocrinology 117:1409-1417(1985)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

Cross-references
Cell line databases/resources DepMap; ACH-002325
LINCS_HMS; 51095
LINCS_LDP; LCL-2076
Ontologies EFO; EFO_0001199
Chemistry resources PharmacoDB; LY2_874_2019
Gene expression databases ArrayExpress; E-TABM-157
GEO; GSM1053705
GEO; GSM1172972
GEO; GSM1172879
Other Wikidata; Q54904374
Polymorphism and mutation databases Cosmic; 1136350
Entry history
Entry creation06-Jun-2012
Last entry updated06-Sep-2019
Version number18